Anticancer therapy induced cardiotoxicity: review of the literature

被引：67

作者：

Geiger, Sandra ^{[1
]}

Lange, Veronika ^{[1
]}

Suhl, Patricia ^{[1
]}

Heinemann, Volker ^{[1
]}

Stemmler, Hans-Joachim ^{[1
]}

机构：

[1] Univ Munich, Med Dept Haematol & Oncol 3, D-81377 Munich, Germany

来源：

ANTI-CANCER DRUGS | 2010年 / 21卷 / 06期

关键词：

anthracyclines; cardiotoxicity; chemotherapy; trastuzumab; BRAIN NATRIURETIC PEPTIDE; METASTATIC BREAST-CANCER; CONGESTIVE-HEART-FAILURE; VENTRICULAR EJECTION FRACTION; LONG-TERM SURVIVORS; ANTHRACYCLINE-INDUCED CARDIOTOXICITY; TRASTUZUMAB-RELATED CARDIOTOXICITY; CARDIAC MAGNETIC-RESONANCE; CAUSE-SPECIFIC MORTALITY; CORONARY-ARTERY-DISEASE;

D O I：

10.1097/CAD.0b013e3283394624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Innovative anticancer strategies have contributed to an improved survival of patients suffering from malignancies, and in some cases, have turned cancer into a chronic disease. Therefore, the early and particularly late onsets of adverse cardiovascular effects of systemic anticancer treatments are of increasing interest. Among a rapidly increasing variety of anticancer drugs, the anthracyclines and the monoclonal antibody, trastuzumab, are the agents with a well-known cardiotoxicity. The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study. Anti-Cancer Drugs 21:578-590 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

引用

页码：578 / 590

页数：13

共 169 条

[1]

Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0

[2] Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy [J].

Adams, MJ ;

Lipsitz, SR ;

Colan, SD ;

Tarbell, NJ ;

Treves, ST ;

Diller, L ;

Greenbaum, N ;

Mauch, P ;

Lipshultz, SE .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3139-3148

[3]

AKHTAR SS, 1993, ONCOLOGY, V50, P441

[4] Mitral regurgitation after anthracycline treatment for childhood malignancy [J].

Allen, J ;

Thomson, JDR ;

Lewis, IJ ;

Gibbs, JL .

HEART, 2001, 85 (04) :430-432

[5] FLUOROURACIL CARDIOTOXICITY [J].

ANAND, AJ .

ANNALS OF PHARMACOTHERAPY, 1994, 28 (03) :374-378

[6] Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement - Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study [J].

Anwaruddin, S ;

Lloyd-Jones, DM ;

Baggish, A ;

Chen, A ;

Krauser, D ;

Tung, R ;

Chae, C ;

Januzzi, JL .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (01) :91-97

[7]

ARBUCK SG, 1993, MONOGR NCI, V15, P117

[8] Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies [J].

Auner, HW ;

Tinchon, C ;

Linkesch, W ;

Tiran, A ;

Quehenberger, F ;

Link, H ;

Sill, H .

ANNALS OF HEMATOLOGY, 2003, 82 (04) :218-222

[9] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[10] Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer [J].

Baselga, Jose ;

Perez, Edith A. ;

Pienkowski, Tadeusz ;

Bell, Richard .

ONCOLOGIST, 2006, 11 :4-12

← 1 2 3 4 5 6 7 8 9 10 →